“We are excited to join the Mirion family and continue our evolution as the benchmark for dose measurement and calibration. This acquisition is recognition of Capintec’s leadership in the nuclear medicine market, world-class technology and strong global footprint. We are confident that Mirion will add significant value and expertise as Capintec executes on its growth strategy while delivering innovative technologies.” says John Viscovic, CEO at Capintec, Inc.